Filtered By:
Condition: Heart Valve Disease

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 554 results found since Jan 2013.

Clinical burden associated with postsurgical complications in major cardiac surgeries in Asia ‐Oceania countries: A systematic review and meta‐analysis
ConclusionsThere are opportunities to improve clinical outcomes of patients with high surgical risks and those undertaking heart valve procedures, as they tend to have poorer survival and higher risk in developing postsurgical complications.
Source: Journal of Cardiac Surgery - August 1, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Teerapon Dhippayom, Piyameth Dilokthornsakul, Vayroj Laophokhin, Nantawarn Kitikannakorn, Nathorn Chaiyakunapruk Tags: ORIGINAL ARTICLE Source Type: research

Surgical left atrial appendage occlusion in patients with atrial fibrillation undergoing mechanical heart valve replacement.
CONCLUSIONS: Concomitant SLAAO and MHVR was associated with longer length of stay, and cardiopulmonary bypass time and aortic cross-clamp time, but was not associated with additional protective effects against thromboembolic events and mortality during the 14-month follow-up. PMID: 32740149 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - July 23, 2020 Category: General Medicine Authors: Zheng Y, Rao CF, Chen SP, He L, Hou JF, Zheng Z Tags: Chin Med J (Engl) Source Type: research

Transcarotid vs Subclavian/Axillary Access for Transcatheter Aortic Valve Replacement with SAPIEN 3.
CONCLUSIONS: TC TAVR is associated with similar mortality and significant reduction in stroke compared to the subclavian/axillary approach. If femoral access is precluded, TC may be a safe, or at times, preferred avenue of transcatheter valve delivery. PMID: 32712098 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - July 22, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Kirker E, Korngold E, Hodson RW, Jones BM, McKay R, Cheema M, Heimansohn D, Moainie S, Hermiller J, Chatriwalla A, Saxon J, Allen KB Tags: Ann Thorac Surg Source Type: research

Novel oral anticoagulant vs. warfarin in elderly atrial fibrillation patients with normal, mid ‐range, and reduced left ventricular ejection fraction
ConclusionsIn elderly AF patients ≥65 years, using NOAC was associated with lower IS/SE compared with warfarin in normal and mid‐range LVEF but not in reduced LVEF. Using NOACs was associated with lower death compared with warfarin in normal LVEF.
Source: ESC Heart Failure - July 15, 2020 Category: Cardiology Authors: Victor Chien ‐Chia Wu, Chun‐Li Wang, Cheng‐Hung Lee, Yu‐Ling Chen, Hui‐Tzu Tu, Michael Wu, Chang‐Fu Kuo, Shao‐Wei Chen, Yu‐Tung Huang, Ming‐Shien Wen, Shang‐Hung Chang Tags: Original Research Article Source Type: research

Aortic and mitral valve surgery for infective endocarditis with reconstruction of the intervalvular fibrous body: an analysis of clinical outcomes.
Conclusions: The double-valve replacement and AMC reconstruction (the Commando procedure) is an effective technique in complex heart valve disease. The short- and mid-term results with this technique are optimal, with a very low in-hospital mortality and nearly 100% of long-term survival during follow-up. PMID: 32395280 [PubMed]
Source: Journal of Thoracic Disease - May 13, 2020 Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research

TAVR equivalent to surgery at 2 years among low-risk patients
(American College of Cardiology) Patients undergoing transcatheter aortic valve replacement (TAVR) fared equally well compared with those undergoing open heart valve replacement surgery in terms of the combined risk of death, stroke or rehospitalization at two years, the primary endpoint of the PARTNER 3 trial being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Impact of Valvular Heart Disease on Mortality, Thromboembolic and Cardiac Events in Japanese Patients With Atrial Fibrillation 　- The Fushimi AF Registry.
CONCLUSIONS: Although VHD did not significantly affect thromboembolism or mortality, it affected cardiac events depending on type, with aortic valve diseases having higher risk, in Japanese patients with AF. PMID: 32213725 [PubMed - as supplied by publisher]
Source: Circulation Journal - March 24, 2020 Category: Cardiology Authors: Doi K, Ogawa H, Ishigami K, Ikeda S, Aono Y, Hamatani Y, Fujino A, An Y, Ishii M, Iguchi M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Akao M, Fushimi AF Registry Investigators Tags: Circ J Source Type: research

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Abbott Wins Approval for CATALYST Trial for At-Risk Stroke Patients
This study is an extremely important step in assessing the Amplatzer Amulet as an effective non-prescription drug alternative for patients with AFib who are at an increased risk for ischemic stroke." In an email sent to MD+DI, Abbott wrote, “We already have an Amulet IDE trial underway that is intended to support our submission for approval in the U.S. for Amplatzer Amulet. The newly announced CATALYST trial will support our submission for an expanded indication for Amulet as a safe and effective alternative to NOAC drugs for patients with atrial fibrillation and at risk of stroke.” Abbo...
Source: MDDI - February 3, 2020 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Regulatory and Compliance Source Type: news

Reducing the risk of blood clots in artificial heart valves
(University of Bern) People with mechanical heart valves need blood thinners on a daily basis, because they have a higher risk of blood clots and stroke. Researchers at the ARTORG Center of the University of Bern, Switzerland, now identified the root cause of blood turbulence leading to clotting. Design optimization could greatly reduce the risk of clotting and enable these patients to live without life-long medication.
Source: EurekAlert! - Medicine and Health - January 13, 2020 Category: International Medicine & Public Health Source Type: news

Aspergillus fumigatus endocarditis in a splenectomized patient with no risk factors
Publication date: Available online 9 January 2020Source: IDCasesAuthor(s): Abhimanyu Aggarwal,, Karen Hogan,, Armando Paez,AbstractAspergillus endocarditis is a rare cause of culture-negative fungal endocarditis, after Candida endocarditis. Typical risk factors include intravenous drug use, immunosuppression, prior cardiac surgery or presence of prosthetic heart valves, hematopoietic stem cell or solid organ transplantation. Common presentations include signs and symptoms consistent with endocarditis but with negative bacterial blood cultures. Here, we present a case report of a 49-year-old male without known risk factors ...
Source: IDCases - January 9, 2020 Category: Infectious Diseases Source Type: research

Is oral anticoagulation effective in preventing transcatheter aortic valve implantation failure? A propensity matched analysis of the Italian Transcatheter balloon-Expandable valve Registry study
Conclusion After TAVI with Edwards Sapien valve OAT did not reduce the incidence of valve dysfunction and stroke but was responsible for mortality and bleeding increases.
Source: Journal of Cardiovascular Medicine - December 27, 2019 Category: Cardiology Tags: Research articles: Interventional cardiology Source Type: research

Impact of Severity of Chronic Kidney Disease on Management and Outcomes Following Transcatheter Aortic Valve Replacement With Newer-Generation Transcatheter Valves.
CONCLUSIONS: In this prospective study of adults undergoing TAVR with newer-generation THVs, moderate and severe CKD was associated with a nearly 2-fold and 3-fold higher risk of 30-day readmission, respectively. PMID: 31841995 [PubMed - as supplied by publisher]
Source: The Journal of Invasive Cardiology - December 18, 2019 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Sapien 3 Ultra balloon-expandable transcatheter aortic valve: in-hospital and 30-day results from the multicentre S3U registry.
CONCLUSIONS: This first multicenter international experience of transfemoral TAVI with the SAPIEN 3 Ultra transcatheter heart valve shows excellent in-hospital and 30-day clinical outcomes. PMID: 31763985 [PubMed - as supplied by publisher]
Source: EuroIntervention - November 27, 2019 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research